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Autologous tissue engineered vascular grafts (TEVGs) are limited by graft 
stenosis. Small diameter TEVGs implanted as unseeded scaffolds are prone to failure by 
occlusive luminal proliferation of smooth muscle cells derived from endothelial 
precursors within a critical period of two weeks. The development, validation, and 
application novel platform for controlling TEVG performance by local delivery of 
peptide and/or small molecule therapeutic agents from the TEVG scaffold is presented 
with insights into the autologous TEVG biology and development. 
We hypothesized that inhibition of TGF-βR1 by local delivery of SB-431542, a 
competitive inhibitor of ALK5/TGFβR1 signaling, is superior to systemic administration 
of SB-431542 in the prevention of EndMT-mediated neointimal hyperplastic stenosis of a 
TEVG during the critical period for graft failure in a mouse model. Specific aims 
included the development of a multiplexed hybrid drug release platform for delivery of 
small molecule and/or protein species from a TEVG scaffold; validation of the clinical 
utility of local versus systemic delivery of SB-431542 in the prevention of TEVG 
neointimal hyperplastic stenosis in a small animal model; and exploration of TGF-β1 
signaling in EndMT and TEVG neointimal hyperplastic stenosis. 
Local delivery of SB-431542 or recombinant human TGF-β1 prevented stenosis 
of a small diameter TEVG. Optimization of the local delivery platform achieved 
maximum therapeutic efficacy with lower costs than systemic therapy. TGF-β1 signaling 
is central to endothelial-mesenchymal transition in TEVG dysfunction. Translation of this 
technology for vascular interventional therapy the hypoplastic left heart syndrome has the 
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“Age was respected among his people, but achievement was revered. As the elders said, 
if a child washed his hands he could eat with kings.”  
― Chinua Achebe, Things Fall Apart 
 
As a child, my first dream child was to be an inventor. The light and shoulders of those 
who made this work possible have carried me toward the realization of that dream. A 
testament to the clarity of their guidance and the power of our collective efforts is the 
submission of this work as a component of: 
 
Yale University, Breuer CK, Fahmy T, Simons M, Chen PY, Duncan DR, 
Patterson JT. Compositions and method for treating and preventing neointimal 
stenosis. International Patent Application No. PCT/US2012/40759. 6 December 
2012. 
 
My second, somewhat more specific, dream was to be an orthopaedic surgeon-scientist. 
My intent with this project was always to acquire principles of tissue engineering for 
application in that field. To continue down the avenue of research detailed herein – which 
I believe to be a noble endeavor, and a great privilege to have scratched the surface of – 
would have been to stray from my professional and personal ambitions. As the Breuer 
research group left Yale for Ohio State University/Nationwide Children’s Hospital, I 
apprehensively submitted an application for a Howard Hughes Medical Institute Medical 
Research Fellowship to support an additional year engaged in more of this research, work 
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very remotely related to my intended career path and geographically isolated from the 
personal relationships that sustain me. 
 
Subsequent clinic experiences in the third year of medical school made it exquisitely 
clear which professional avenue would be the most fulfilling for me. I chose to decline 
the HHMI award and complete medical school in four years. This was a choice that I 
alone made and one that I may always question. I am grateful for the generosity and 
understanding of those affected by my errant perfidy, and that a more deserving peer at 
Yale received and made outstanding that fellowship support. 
 
Shamefully absent from this thesis document are the would-be products of that 
abandoned research year: the likely application of this system toward further 
investigations of vascular tissue engineering and whatever may have followed.  
 
Joseph Thomas Patterson 
31 December 2013 
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Congenital heart disease in the United States 
Congenital heart disease is both the most common and most lethal congenital 
anomaly, affecting 1% of live births in the United States. The leading cause of death 
among congenital anomalies in the newborn period, congenital heart disease accounts for 
more pediatric deaths than all childhood cancers combined. Half of all infants born with 
CHD require surgical intervention to establish cardiovascular continuity that can support 
growth and prevent development of arrhythmias, developmental disorders, congestive 
heart failure, and early death
1
.  
Of the manifold forms of congenital heart disease, the univentricular physiologies 
including hypoplastic left heart, tricuspid atresia, and pulmonary atresia represent the 
most severe variety of congenital heart disease. The univentricular physiologies account 
for the highest treated and untreated mortality as well as the highest treatment costs
2
. 
Untreated mortality ranges from 70-95% in the first year of life. Surgical correction, in 
the form of staged palliative operations which moderately reduce mortality at substantial 




The inadequacy of current care for these diseases warrants the devotion of 
research resources to further characterization and the development of more effective 
treatment solutions. Our group has chosen to focus on the most individually burdensome 
and refractory of the single ventricle physiologies as the disease entity and patient 
population that stand to reap the greatest gains from such efforts. Hypoplastic left heart 





. Though one of the least common forms of congenital heart disease, 
hypoplastic left heart syndrome continues to frustrate clinicians as the most lethal variant 





Hypoplastic left heart-syndrome 
The “hypoplastic left heart” describes a spectrum of left heart hypoplasia with no 
single pathogenic etiology. The variable constellation of observed anomalies amount to a 
physiologically inadequate cardiopulmonary system that precipitates universally fatal 
ischemic congenital heart disease. Variable hypoplasia of the mitral valve, aortic valve, 
and ascending aorta combined with fibroelastosis of the left ventricle render systemic 
perfusion dependent upon a single hypofunctional ventricle. Simultaneous arteriovenous 
mixing via both a patent ductus arteriosus and a nonrestrictive patent foramen ovale are 
necessary to sustain life. Without treatment, physiologic postnatal ductal closure and 
falling pulmonary vascular resistance precipitate hypoxemia, acidosis, and shock. 
Untreated mortality exceeds 95% within the first month of life
5
.  
The popular mechanistic theory of the development of hypoplastic left heart 
syndrome describes a primary isolated left-sided defect that disrupts load- or flow-
dependent fetal development of other left heart structures. In one example, critical aortic 
stenosis in the second trimester leads to a normal-sized or dilated left ventricle, retrograde 
flow across the transverse arch and foramen ovale, and monophasic mitral valve inflow 
that progresses to left heart hypoplasia and univentricular physiology at birth
6
. Genetic 
associations with Patau, Edward, Turner, and Jacobsen syndromes, GJA1, NKX2-5, 
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NOTCH1, and HAND1 mutations, and 10 loci of undetermined significance as well as 
familial associations with bicuspid aortic valve speak to the heterogeneic etiologies of 
hypoplastic left heart syndrome
7
. Environmental associations are unclear; in utero 






Figure 1. Staged surgical correction of hypoplastic left heart syndrome, (A) Schematic 
representation of anatomical defects comprising the hypoplastic left heart syndrome. (B) 
Stage I Norwood procedure. (C) Stage I Hybrid alternative to Norwood procedure. (D,E) 
Stage II Blalock-Taussig (D) or Sano shunt from right ventricle to right atrium. (F) Stage 
III modified Fontan procedure with extracardiac shunt from inferior vena cava to right 
pulmonary artery achieves total cavopolumonary connection. Reproduced with 





State of current therapy 
Surgical therapy is the mainstay of definitive treatment for hypoplastic left heart 
syndrome. Five-year survival now approaches 65-77% after staged Norwood palliation
9,10
 
and 76-84% after cardiac transplant
11,12
. However, mortality on the transplant waiting list 
varies regionally from 20-40%
13
. The lack of appropriate cardiac donors has solidified 




Treatment begins at birth with prostaglandin E1 to maintain patency of the ductus 
arteriosus and temporarily preserve systemic circulation. The surgical stage I, the 
Norwood procedure, is typically performed within the first week of life. The pulmonary 
artery and pulmonary valve are incorporated into the aortic arch, forcing the right 
ventricle to assume the functional position of the hypoplastic left ventricle as the 
physiologic driver of bloodflow to both the systemic and pulmonary circuits. An atrial 
septostomy routes pulmonary venous return to the right ventricle. A Blalock-Taussig or 
Sano shunt recirculates mixed venous return and oxygenated blood from the lungs to the 
pulmonary arteries, enhancing the oxygen saturation of blood entering the systemic 
circuit at the cost of increased dynamic load for the right ventricle. An alternative hybrid 
approach to Stage I palliation involves ductal stenting, transcatheter atrial septoplasty, 
and pulmonary artery banding. Hybrid stage I palliation and improved perioperative 
management account for recent modest improvements in survival
3
. 
Stage II palliation is performed at 4-6 months of age. The aortic repair is 
completed and a bidirectional Glenn shunt or hemi-Fontan shunt is installed to route 
blood from the superior vena cava(s) directly to the pulmonary artery and unload the right 
11 
 
atrium. The Blalock-Taussig or Sano shunt is taken down to unloads the right ventricle. 
Stage II boosts arterial oxygen saturation to approximately 80%.  
Stage III, the completion, modified, or hemi-Fontan procedure is performed at 2-4 
years of age, when the diameter of the pediatric inferior vena is typically 60-80% that of 
the adult IVC.  This operation fully relieves cyanosis by routing the inferior vena cava to 
the pulmonary arterial circulation with an adult-size (20-22 mm) vascular conduit. The 
original Fontan, developed in the 1970s, directly connected the right atrium to the 
pulmonary artery but the size mismatch between the IVC and atrium produced 
nonlaminar blood flow from the IVC to the atrium and was associated with unacceptably 
high rates of morbidity and mortality
14,15
. The modified Fontan most commonly 
performed uses an extracardiac conduit to channel blood from the inferior vena cava 
directly to the right pulmonary artery. This extracardiac total cavopulmonary connection 
bypasses the right atrium, thus maintaining laminar flow and increasing the flow of blood 
through the pulmonary circulation
16
. However, complications arising from the use of 
synthetic vascular grafts are a leading source of morbidity and mortality
17,18
. No existing 
vascular graft is an ideal conduit for the extracardiac total cavopulmonary connection. 
Polytetrafluoroethylene (PTFE or Gore-Tex) conduits, which have a lower failure rate 
than Dacron
19
, are currently the most widely used vascular grafts for this operation
20
. 





Figure 2 (opposite). Gary Kopf, MD, and Toshiharu Shinoka, MD, implant the first tissue 
engineered-vascular graft for the treatment of pediatric congenital heart disease in the 








Characterization of TEVGs in animal models 
 
 





Expanded autologous vascular cell lines were seeded onto biodegradable 
scaffolds of tubularized polyglactin or 50:50 copolymer of L-lactide and -caprolactone 
polywoven (PCLA) mesh sealed with nonwoven polyglycolic acid (PGA) mesh. Seeded 
or unseeded constructs were implanted as interposition grafts replacing 2 cm sections of 
the main pulmonary artery in juvenile lambs (polyglactin, N=8) or as thoracic IVC 
interposition grafts in dogs (PCLA, N=4). At six months after implantation, all seeded 
scaffolds were patent without anticoagulation, possessed an endothelial lining and overall 
14 
 
morphology resembling native pulmonary artery, and demonstrated non-aneurysmal 
increase in size. Conversely, unseeded scaffolds formed thrombi and stenosed within two 
weeks of implantation
23,24
. These results highlighted the importance of cell seeding for 
TEVG performance but did not elucidate the mechanism by which seeded cells affected 
TEVG development. 
Prior studies by other investigators had demonstrated that vascular grafts seeded 
with bone marrow cells (BMCs) formed an endothelial monolayer
25
. Rapid 
endothelization is desirable because healthy ECs reduce the immediate thrombogenicity 
and immunogenicity of the TEVG and enhance long-term patency
26
 . Bone marrow also 
contains endothelial progenitor cells (EPCs) that may contribute to graft 




Autologous BMCs enriched for the mononuclear fraction (BM-MNCs) were 
statically seeded on PCLA/PGA scaffolds, cultured for two hours, and implanted as 
interposition grafts replacing the intra-thoracic IVC in an adult beagles (N=16). All 
seeded grafts were patent up to two years without evidence of thrombosis, stenosis or 
aneurysm formation. Seeded BM-MNCs adhered to the scaffold before implantation. 
Autologous BM-MNCs could be used as a practical cell source for creating TEVGs, 
enabling rapid cell harvest without the need for cell culture
28
. 
Further investigations were performed in a sub-1-mm TEVG mouse model that 
recapitulates the development of its human and lamb counterparts on a more rapid time 
scale
29
. When implanted as interposition grafts, these small diameter scaffolds undergo 





tracing studies revealed that endothelial and smooth cells migrate in from the adjacent 
vessel to cover the lumen in concentric layers
30
 while circulating macrophages take up 
residence between the scaffold fibers
31
. Seeding the bare scaffold with BM-MNCs before 
implantation enhanced graft patency rates and accelerated macrophage and endothelial 
cell infiltration. However, MRI tracking demonstrated that the seeded cells rapidly 
departed the scaffold
32
. Seeded cells attracted and influenced the behavior of their 
cellular successors via a paracrine mechanism involving the deposition of cytokines 




Limitations of cell seeded scaffolds 
Manufacturing fully autologous tissue outside of the patient before implantation is 
expensive; such endeavors require a great deal of time, equipment, facilities, and 
personnel, and are prone to defects and contamination throughout the fabrication period. 
Ex-vivo expansion of fully differentiated autologous vascular cell lines can take weeks, 
and is especially time consuming with tissues derived from patients with vascular disease 
and other systemic illnesses. Even bone marrow-derived stem cells, which may be 
harvested, processed, and seeded on a scaffold to create a Fontan conduit that is 
implanted on the same day as harvesting, requires a large team of personnel and more 
than eight hours of general anesthesia. Such limitations and challenges make the prospect 
of an unseeded scaffold very alluring. 
Cytokine release from unseeded TEVG scaffolds can modulate the host response 
to an implanted TEVG to achieve a similar graft phenotype and patency rate as those 
attained with cell seeded grafts
22
. This observation that cytokine signaling can substitute 
16 
 
for cell seeding in TEVG formation encouraged our pursuit of a “cell-free approach” to 
tissue engineering whereby scaffolds are modified to slowly release signals that direct 




Cell-free paradigm: drug and cytokine release 
Integration of a biomedically engineered drug delivery system with the well-
studied TEVG scaffold will be central to the fabrication vascular grafts that can control 
the cellular and molecular processes responsible for neovessel formation. The patient 
tissues become employees in the assembly line while the scaffold acts as a foreman and 
blueprint and the cytokines function as instructions. 
A cell-free TEVG will eliminate the need for biopsy, ex-vivo culture, and seeding 
of recipient cells – existing challenges to clinical use of TEVG. This will render 
autologous vessel or bone marrow harvest unnecessary and furnish drastic reductions in 
economic, personnel, and facility requirements. Moreover, properly stored cytokine-
eluting vascular grafts may have shelf lives potentially comparable to PTFE and Dacron 
grafts. Further characterization of the natural history of TEVG development will inform 
the selection of cytokines with which to incorporate into scaffolds to improve TEVG 
performance. The era of an off-the-shelf vascular graft that grows with the patient and 
behaves like or better than a native vessel is in sight. 
The questions, central to this thesis, then become: (a) what process(es) should be 
targeted to improve TEVG performance; (b) what intervention(s) should be performed; 





The target: TGF-β1 signaling in endothelial-mesenchymal transition  
 
Figure 4. TGF-β signaling pathways in vascular endothelial cells. Reproduced with 




TEVGs provide decreasing vascular resistance over time via neovessel growth, 
but unregulated growth may become pathologic. The primary mode of TEVG failure in 
humans and animals is luminal stenosis characterized by hyperplastic graft wall 
thickening and vessel occlusion
36,37
. Excess TGF-β1 protein and mRNA are present in 
stenosed and unseeded small diameter TEVGs. Our group demonstrated that TGF-β1-
driven endothelial-mesenchymal transition (EndMT) is the primary mechanism of TEVG 
stenosis, which is the sole observed mechanism of TEVG dysfunction
38
. Targeting the 
EndMT process, then, would be the most logical way to improve TEVG clinical utility. 
18 
 
EndMT is a subset of the epithelial-mesenchymal transition essential during 
cardiac development and tissue regeneration that also underlies pathologic conditions 
such as cardiac and hepatic fibrosis and several forms of cancer
39
. EndMT occurs when 
endothelial cells and endothelial cell progenitors lose their cell junctions, delaminate 
from the vessel lumen, and invade the underlying tissue. These cells exhibit loss of 
endothelial markers (CD31, Pecam-1, VE-cadherin) and acquisition of mesenchymal 
markers (SMA, N-cadherin)
40
. The EndMT process is essential during cardiac 
development and tissue regeneration but also underlies pathologic conditions such as 
cardiac and hepatic fibrosis and several forms of cancer
39
.  
 Though its effects are concentration-dependent, TGF-β1 induces mouse 
endothelial cells to undergo EndMT in vitro by signaling primarily through canonical 
Smad activation and possibly via non-canonical MEK, PI3K, and p38 MAPK 
pathways
41,42
. Activin receptor-like kinase 5 (ALK5) is the dominant mediator of TGF-β1 
signaling in mouse endothelial cells: TGF-β1 → ALK5/ TGF-β1RII → Smad2/3 
phosphorylation disrupts endothelial remodeling by suppressing expression of inhibitor 
of differentiation-1 (Id1)
43,44
. Conversely, TGF-β/BMP → ALK1/TGF-β1RII → p-
Smad1/5 enhances vessel remodeling by upregulating Id1 and PAI-1
45
. Pathway 
dominance of ALK1 vs. ALK5 depends upon TGF-β1 concentration and duration of 
exposure
44
. Though ALK1 activity in vitro elicits responses that are opposite those 
observed with ALK5 stimulation, the relationship between ALK1 and ALK5 signaling 
and subsequent endothelial cell behavior is complicated by ligand exposure time and 






TGF-β1 type II receptors phosphorylate the polarity protein PAR6 which leads to 
the disassembly of tight junctions
46
. c-Abl and PKC-δ kinases also appear critical for 
TGF-β-mediated EndMT
47
. However, the effect of TGF-β1 concentration and exposure 
time on EndMT in vivo is unknown. Endothelial and vascular smooth muscle cells 
constitutively produce TGF-β1, and activation of these cells attenuates endogenous TGF-
β1 production.  
 TGF-β1 promotes mouse endothelial cell proliferation and migration at low 
concentrations but is inhibitory at high concentrations
35
. This paradox appears related to 
both the intensity and duration of the signal as well as competition between parallel Smad 
pathways. Activin receptor-like kinase 5 (ALK5) is the dominant type I TGF-β receptor 
in endothelial cells; TGF-β11 → ALK5/ TGF-β1RII → Smad2/3 phosphorylation 
suppresses expression of inhibitor of differentiation-1 (Id1) and obstructs angiogenesis by 
inhibiting endothelial cell proliferation, migration, and organization. Though some 





The intervention: SB-431542, a small-molecule ALK inhibitor 
SB-431542 is a potent and specific but poorly soluble inhibitor of Alk5, the 
dominant type I TGF-β receptor in endothelial cells
48,49
. D. R. Duncan and colleagues 
demonstrated that systemic administration of this inhibitor in a mouse model of TEVG 






Long-term administration of SB-431542 which has quantifiable activity at range 
of tyrosine kinases widely distributed through numerous tissues
48
 can be reasonably 
expected to have off-target, potentially deleterious, effects. Moreover, metabolism of this 
molecule necessitates twice daily intraperitoneal or intravenous dosing, which makes 
therapeutic use decidedly impractical. 
 
The vehicle: tethered biodegradable microparticles 
Controlled release is a powerful method for delivering therapeutic concentrations 
of biologically active agents directly to the site of their activity by the degradation of or 
elution from a bulk material, or carrier, placed proximate to that target site
50
. Synthetic 
biodegradable polymers including the two polymers used in the construction of the 
TEVG scaffold mentioned previously have been used extensively as controlled release 
carriers
51
. Micro- and nano-sized synthetic polymer particles are a particularly attractive 
carrier technology from a design perspective because the fabrication process can be finely 
controlled to tune the release profile of the therapeutic agent contained within; moreover, 
such particles can be functionalized with various surface moieties, such avidin,  that 
facilitate particle conjugation with biologically active or functionally useful molecules
52
. 
However, particles are free floating spheres that may be detached from a surface 
and thus leave the target site. If particles are to be used form sustained deliver, especially 
in a high-shear environment such as the lumen of a vascular graft, they would need to be 
tethered in place. 
Coatings of poly-L-lysine conjugated to various targeting molecules have been 





positively charged polyamine group of poly-L-lysine interacts adhesively with the partial 
negative functional groups of other polymers including as the polyester groups of the 
poly(glycolic acid) (PGA) and poly((caprolactone-lactic acid) (PCLA) polymer 
constituents of the TEVG scaffold. The weak hydrostatic and van der Waals forces 
underlying this adhesion are duplicated over a substantial surface area at the interface of 
the these polymers, collectively enabling a strong connection between the TEVG 
scaffold, the linker polymer, and SB-431542-eluting particles. 
 
Statement of purpose 
This thesis is an application of biomedical engineering principles and techniques 
with the above accrued understanding of the pathophysiology of our novel treatment for 
hypoplastic left heart syndrome for the purpose of developing of the next generation 
tissue engineered vascular graft. Informed biologic direction of TEVG growth and 
development in situ might enhance graft performance and permit earlier graft use, 
perhaps even single stage palliative surgery, with further improvements in outcome for 
this patient population. Understanding of the role of endothelial mesenchymal transition 
in vascular neotissue formation is expected to yield far wider-ranging applications to the 







Inhibition of TGF-βR1 by local delivery of SB-431542 is superior to systemic 
administration of SB-431542 in the prevention of EndMT-mediated neointimal 
hyperplastic stenosis of a TEVG during the critical period for graft failure in a mouse 
model. 
 
Specific aims  
1. Develop multiplexed hybrid drug release platform for delivery of small molecule 
and/or protein species from previously investigated TEVG scaffold 
a. Encapsulate candidate therapeutics in release vehicle 
b. Tether release vehicle to TEVG scaffold to minimize loss of release 
vehicle and off target delivery of therapeutic agent 
c. Optimize loading of TEVG scaffold with release vehicle 
d. Characterize release of therapeutics from scaffold 
e. Confirm therapeutics encapsulated in delivery platform retain bioactivity 
2. Validate clinical utility of local versus systemic delivery of SB-431542 in the 
prevention of TEVG neointimal hyperplastic stenosis in a small animal model 
a. Demonstrate local delivery of SB-431542 is more efficacious than 
systemic delivery of SB-431542 
b. Demonstrate local delivery of SB-431542 is more economical than 
systemic delivery of SB-431542 
c. Show efficacy of inhibition of TGF-βR1 signaling by SB-431542 is 
dependent upon the release profile of SB-431542 
23 
 
3. Explore TGF-β1 signaling in EndMT and TEVG neointimal hyperplastic stenosis 
a. Validate previous findings that systemic SB-431542 therapeutically 
prevents EndMT by replicating results with local delivery 
b. Investigate possible disparate effects of delivery of rhTGF-β1 versus SB-





All procedures and methods described in this section were developed and 
performed by the author unless otherwise stated. All figures, photographs, and schematics 
are original unless otherwise stated. 
 
Scaffold fabrication 
TEVG scaffolds were constructed from a nonwoven polyglycolic acid (PGA) 
mesh (Concordia Fibers) and a co-polymer sealant solution of poly-L-lactide and –ε-
caprolactone (P(CL/LA)) as previously described
55
. Briefly, tubular scaffolds were 
formed by compressing a 6.0 mm x 6.0 mm sheet of nonwoven P(CL/LA) felt between a 
21-gauge stainless steel rod (to maintain the inner lumen) and a cylindrical cored-out 
polypropylene rod. The polymeric scaffolds were coated with a 50:50 copolymer sealant 
solution of poly– -caprolactone-l-lactide (263,800 Da; Absorbable Polymers 
International, Birmingham, Ala) dissolved at 5% wt/vol in dioxane. Scaffolds were snap 





SB-431542-eluting scaffold fabrication 
SB-431542-eluting PGA-P(CL/LA) scaffolds were fabricated as above except for 
the substitution of 5% w/v P(CL/LA)  with a 5% w/v P(CL/LA) solution containing 3 
mg/ml SB-431542 dissolved in dioxane. The quantity of SB-431542 per scaffold was 
derived from a density balance calculation such that each scaffold would contain 1/1000 
the cumulative mass of intraperitoneal SB-431542 administered as intraperitoneal 




Figure 5. Schematic representation of microparticle synthesis by encapsulation of rhTGF-
β1 or SB-431542 in avidin-coated PLGA. 
 
SB-431542 (Sigma-Aldrich Cat. No. S4317) was encapsulated in avidin-coated 
PLGA microparticles using a modified oil/water single emulsion technique as previously 
described
52,56
. Briefly, 5 mg of drug and 100 mg PGLA (50/50 monomer ratio, Durect 
Corp. Cat. No. B0610-2) dissolved in 2 ml chloroform and 200 ul DMSO were added 
dropwise with vortexing to 4 mL of aqueous surfactant solution containing 2.5 mg/mL 
polyvinyl alcohol (PVA) (Sigma-Aldrich Cat. No. 363138) and 2.5 mg/mL 
25 
 
avidin−palmitate bioconjugate to create an emulsion containing microsized droplets of 
polymer/solvent, encapsulated SB-431542 and surfactant. Solvent was removed by 
magnetic stirring at 20C; hardened microparticles were then washed 3× in DI water and 
lyophilized for long-term storage at -20C. Null vehicle control avidin-coated PLGA 
microparticles were synthesized as above without SB-431542.  
Recombinant human TGF-β1 (rhTGF-β1) expressed in HEK 293 cells 
(Humakine, Sigma-Aldrich Cat. No. 8541) was encapsulated in avidin-coated PLGA 
microparticles using an water/oil/water emulsion technique. 1.0 ug rhTGF-β1 in PBS was 
encapsulated in 5 mg PLGA microparticles per above. Calculations considering prior 
studies demonstrating based on 0.2% efficiency of encapsulation of similar hydrophilic 
protein leukocyte inhibitor factor in this particle system
57
 and the relative receptor 
affinity, dissociation constants, and mass comparisons approximating a five-fold lower 




Microparticle size and morphology were analyzed via scanning electron 
microscopy (SEM). Samples were sputter-coated with gold under vacuum in an argon 
atmosphere using a sputter current of 40 mA (Dynavac Mini Coater, Dynavac, USA). 
SEM analysis was carried out with a Philips XL30 SEM using a LaB electron gun with 





Preparation of adhesive peptide tether 
 
Figure 6. Poly-L-lysine-LC-LC-biotin. 
 
Poly-L-lysine-LC-LC-biotin (pLLB) was synthesized and used as an adhesive 
peptide tether to enhance loading of PGA-P(CL/LA) scaffolds with avidin-coated 
microparticles. 1.66 mg EZ-Link sulfo NHS-LC-LC-biotin was reacted with 10 ml of a 
0.1 mg/ml solution of poly-L-lysine (MW 70,000-150,000, Sigma-Aldritch Cat. No. 
P4707 )  in 1x PBS for 2 hours at 4C, dialyzed in 1x PBS for 72 hours, and stored at 4C. 
 
Loading of TEVG scaffolds with release vehicle 
 
 
Figure 7. Schematic representation of microparticle decoration of TEVG scaffold. 
 
Nonspecific adsorption of avidin-coated PLGA microparticles to PGA-P(CL/LA) 
scaffolds not treated with pLLB was titrated by incubating scaffolds trimmed to 5 mm in 
axial length with 1 ml of 1, 5, or 10 mg/ml of microparticles in 1x PBS for 10, 30 or 60 





nitrogen and lyophilized for 6 hours before imaging. Scaffold loading efficiency was 
determined with ImageJ software (Image Processing and Analysis in Java, National 
Institute of Health, Bethesda, MD) from three SEM images per scaffold cross section, 
inner surface, and outer surface by calculating the mean surface density of particles. The 
effect of scaffold pretreatment with pLLB on scaffold loading efficiency was assessed 
from particle loading density as above after PGA-P(CL/LA) scaffolds were incubated 
with 1 ml of 0.01, 0.1 or 1 mg/ml pLLB for 60 minutes on a rotary shaker, washed 3 
times with dH2O, incubated with 1 ml 5 mg/ml avidin-coated PLGA microparticles on a 
rotary shaker, washed 3 times with dH2O, snap frozen in liquid nitrogen, lyophilized for 6 
hours, and imaged by SEM. For in vitro and in vivo studies, PGA-P(CL/LA) scaffolds 
were incubated with pLLB for 30 minutes at 20C on a rotary shaker, washed 3 times with 
dH2O, incubated with 5 mg/ml empty or SB-431542-eluting avidin-coated PLGA 
microparticles for 30 minutes on a rotary shaker, washed 3 times with dH2O, snap frozen 
in liquid nitrogen, and lyophilized for 6 hours before storage in a dessicator. 
 
Characterization of SB-431542 release from microparticles and scaffolds 
Total encapsulation was approximated as the amount of SB-431542 released over 
a 14 day period. Percent encapsulation efficiency was calculated as total encapsulation 
divided by maximum theoretical encapsulation. 5 mg of avidin-coated PLGA 
microparticles containing SB-431542, PGA-P(CL/LA) scaffolds trimmed to 5 mm axial 
length and treated with pLLB and SB-431542-eluting microparticles as above, and SB-
431542-eluting PGA-P(CL/LA) scaffolds trimmed to 5 mm axial length were incubated 
with 400 μl 1x PBS in 2 ml microcentrifuge tubes in triplicate on a rotary shaker at 37C. 
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Samples were removed at time points of 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, 120, 168, 240, 
and 336 hours and centrifuged at 13200 RPM for 10 ten minutes. 300 μl of supernatant 
was drawn and replaced with 300 μl 1x PBS. Concentration of SB-431542 in supernatant 
diluted with 600 μl 1x PB was determined by spectrophotometry at 320 nm in a quartz 
cuvette. 
 
Bioactivity of encapsulated SB-431542by p-SMAD immunoblot 
SB-431542 was released into 1 ml 1x PBS from 10 mg avidin-coated PLGA 
microparticles and one untrimmed SB-431542-eluting PGA-P(CL/LA) scaffold in 2 ml 
microcentrifuge tubes on a rotary shaker at 37C. At 48 hours, samples were centrifuged at 
13200 RPM for 10 ten minutes, supernatants were collected and analyzed by 
spectrophotometry at 320 nm. SB-431542 concentrations were adjusted to 10 μM by 
dilution with 1x PBS. 3T3 human fibroblasts (Sigma Aldrich, Cat. No. 93061524-1VL) 
were plated at 500,000/well on a 6-well plate and stimulated at confluence with 700 ul 10 
μM SB-431542 in PBS eluted from particles or scaffolds, a stock solution of 10 or 1 μM 
SB-431542 containing <1% DMSO, 1 or 1x PBS. After 30 minutes at 37C, cells were 
washed with warm PBS and stimulated with 200 ul 2 ng/ml recombinant human TGF-β1 
(BD Biosciences, Cat. No. 354039) for 1 hour at 37C. Cells were lysed with ice cold 
RIPA lysis buffer containing phosphatase and proteinase inhibitors (PhosSTOP and 
cOmplete mini, Roche Applied Science, Cat. No. 04906845001 and 04693116001). Cell 
lysates were collected in 200 μl ice cold 1x PBS by scraping, vortexed for 15 seconds, 
agitated on a rotary shaker at 4C for 30 minutes, and centrifuged at 12000 RPM for 15 
minutes at 4C. Supernatant protein concentrations were determined by DC protein assay 
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(Bio-Rad Life Science, Hercules, CA) and protein samples were separated by gel 
electrophoresis with a 12% polyacrylamide gel. Samples were transferred to a PVDF 
membrane, blocked with 5% milk, and probed with primary rabbit monoclonal antibody 
against phosphorylated SMAD-2 (ser426/ser428, Cell Signaling Technology, Cat . No. 
3010) and secondary goat anti-rabbit IgG (Cell Signaling Technology, Cat. No. 7074). 
The gel was stripped in stripping buffer (50 ml 62.5 mM Tris-HCl, 2% SDS, 100 mM β-
mercaptoethanol) for 40 minutes at 50C with agitation and reprobed with anti-SMAD2/3 
as a loading control. The proteins were visualized with ECL exposure on HyBlot x-ray 
film. Cell culture and blots were performed by Joseph T. Patterson and Muriel Cleary, 
MD. 
 
Mixed splenocyte scaffold culture 
All animal experiments were done in accordance with the institutional guidelines 
for the use and care of animals as set by the Institutional Animal Care and Use 
Committee (protocol no. 2007-11160 and 2010-11139]). TEVG scaffolds were trimmed 
to 5 mm axial length and sterilized under UV light. A 24 well plate was pretreated with 
2.5 μg/well anti-CD3 (Sigma Aldrich, Cat. No. SAB4700050). Mixed splenocytes were 
collected from a 6 week old Foxp3-GFP C57L/B6 mouse (Jackson Laboratory, Bar 
Harbor, ME), plated at 10
6
 cells/well and stimulated with 2.5 ug/well anti-CD28 (Sigma 
Aldrich, Cat. No. SAB1405583). One PGA-P(CL/LA) TEVG scaffold, one PGA-
P(CL/LA) TEVG scaffold treated with pLLB and avidin-coated PGLA microparticles, 
one PGA-P(CL/LA) TEVG scaffold treated with pLLB and SB-431542 releasing avidin-
coated PGLA microparticles, or one PGA-P(CL/LA) TEVG releasing SB-431542 from 
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the P(CL/LA) phase were incubated with 1 ml stimulated splenocytes for 4 days in 
quadruplicate. Cell proliferation was assessed by cell titer blue assay. IL-2, IL-10, IL-12, 
TGF-β, TNF-α, and INF-γ in supernatant were quantified by ELISA. Cells were stained 
for CD4 on Pacific Blue, CD8 on r-phycoerythrn, and CD25 on on r-phycoerythrn Cy-7.  
Cell populations were assessed by flow cytometry (LSRII, BD Biosciences). 
 
Pre-implantation scaffold processing 
Scaffolds were retrieved from -20°C and lyophilized overnight. Scaffolds were 
coated with fibrin and thrombin. Scaffolds were sterilized at room temperature under UV 
light prior to implantation. Scaffolds used for in vitro release studies were not coated with 
fibrin or thrombin.  
 
Implantation of TEVG scaffolds in C57BL/6 mice  
 All animal experiments were done in accordance with Yale institutional 
guidelines for the use and care of animals, and the institutional review board approved all 
experimental procedures. All animals were housed and cared for in Yale YARC facilities 
in accordance with institutional policy. Experiments were performed as described in 
approved IACUC protocol #2010-10835. 
TEVG scaffolds were implanted into the infrarenal inferior vena cava (IVC) of 8-
10 week old, female mice as previously described 
55
.  Briefly, female C57BL/6 mice (6-8 
wk old, Jackson Laboratory, Bar Harbor, ME) were anesthetized with intraperitoneal 
injections of ketamine (100 mg/kg) (Hospira, Inc, Lake Forest, Ill) and xylazine (10 
mg/kg) (Ben Venue Laboratories, Bedford, Ohio). After preparation and sterilization of 
31 
 
the abdomen with betadine and alcohol, a midline laparotomy incision was made. The 
IVC was identified and exposed using an 18× dissecting microscope (Zeiss, Thornwood, 
NY), and the abdominal cavity bathed in heparinized solution (250 U/mL) (Baxter, 
Deerfield, Ill). Control of the IVC was obtained just inferior to the renal veins and 
superior to the iliac veins. 10 TEVG scaffolds functionalized with avidin-coated PLGA 
microparticles, 10 TEVG scaffolds functionalized with SB-431542-eluting avidin-coated 
PLGA microparticles, and 10 TEVG scaffolds withSB-431542 in the P(CL/LA) phase 
fabricated as above were implanted as infrarenal IVC interposition grafts via 
microsurgical techniques. All anastomoses were preformed in an end-to-end technique 
using 10-0 monofilament nylon sutures (Sharpoint Lab Sutures, Calgary, Alberta, 
Canada) in interrupted stitches. Adequate hemostasis was achieved before closing the 
abdominal cavity. Graft recipients were recovered from surgery on warmed pads and 
evaluated for evidence of hind limb ischemia, paralysis, or acute graft thrombosis before 
being returned to their cages. All mice were maintained postoperatively without the use 
of any anticoagulation or antiplatelet therapy. Surgical implantation of all TEVG 
scaffolds was performed by a single fellowship-trained microsurgeon, Tai Yi, MD.  
 
Explantation and tissue preparation 
 Mice were sacrificed according to Yale IACUC policy and Infrarenal TEVG IVC 
grafts were explanted with adjacent tissue by Tai Yi, MD. Explanted grafts were pressure 
fixed in 10% formalin overnight and embedded in paraffin. Representative grafts (n = 5) 
from each of the 4 study groups were explanted at 2 weeks and evaluated histologically 
and by immunohistochemistry. The grafts were pressure perfused before a 24-hour 
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fixation in 10% formalin as previously described
58
. After fixation, grafts were washed 
with 1× phosphate-buffered saline and placed in 70% alcohol for an additional 24 hours. 
 
Morphometric analysis 
Graft luminal diameters were measured using Image J software. Stenosis was 
defined as greater than 50% decrease in luminal diameter. Graft occlusion was defined as 
100% narrowing of the luminal diameter. TGF-β positive cell area was measured using 
ImageJ software. Two separate sections of each explant were counterstained with 
hematoxalin and Gomori trichrome and imaged at 400X magnification.  
 
Histologic analysis 
Histologic processing and staining were performed by staff of the Bone Histology 
Laboratory, Department of Orthopaedics and Rehabilitation, Yale University School of 
Medicine. Grafts were embedded in paraffin and mounted onto slides (5-μm cuts) 
allowing for graft analysis. Cellularity and morphometry were evaluated by H&E staining 
(Sigma). Collagen was identified using Gomori's trichrome stain (Gomori One-Step 
Trichrome Stain, Dako). Lumen diameter was calculated from Gomori trichrome and 
H&E-stained sections using Image J software. Further characterization of graft and 
neovessel cellular composition was conducted using immunohistochemical techniques. 
Von Willebrand Factor (vWF antibody; Abcam) was used to identify luminal endothelial 
cells, smooth muscle cells were identified by calponin expression(Calponin antibody; 
Abcam), and macrophages were detected using F4/80 (BD Biosciences, San Jose, CA). 
Antibody binding was detected using appropriate biotinylated secondary antibodies, 
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followed by binding of streptavidin-horseradish peroxidase (HRP) and color development 
with 3,3-diaminobenzidine (Vector, Peterborough, United Kingdom). Nuclei were 
counterstained with hematoxylin. 
 
Immunohistochemistry 
Primary antibodies included: calponin, clone hCP (Sigma), CD31 (Abcam), 
smooth muscle α-actin (Dako), vWF (Dako), VE-cadherin (Santa Cruz).  Antibody 
binding was detected using appropriate biotinylated secondary antibodies, followed by 
binding of streptavidin-HRP and color development with 3,3-diaminobenzidine (Vector). 
Nuclei were counterstained with hematoxylin. 
For immunofluorescence, Two separate sections of each explant underwent triple 
immunofluorescent staining with DAPI, SMA, and CD31. Goat-anti-rabbit IgG-Alexa 
Fluor 568 (Invitrogen) or goat-anti-mouse IgG-Alexa Fluor 488 (Invitrogen) was used 
with subsequent 4',6-diamidino-2-phenylindole nuclear counterstaining. 






 Comparison of local and systemic delivery strategies was performed using 
calculated total multiplicative encapsulation efficiency for each delivery route and current 
market pricing of $120 per 5 mg SB-431542.  
 
Statistical analysis 
Two-tailed paired Student’s t-test with the assumption of unequal sample variance 
was used to compare diameters of the various microparticle species as well as luminal 
diameters between the different TEVG scaffold groups after explantation. Two-tailed 
Fisher’s exact test was used to compare rates of occlusion between the different TEVG 









Figure 8. Scanning electron micrograph of tubular PGA-PCLA TEVG scaffold in cross 
section (A) demonstrating internal and external surfaces available for particle loading and 





Figure 9. Scanning electron micrographs of lyophilized avidin-coated PLGA 
microparticles encapsulating (A) null control vehicle, (B) 5 mg SB-431542/100 mg 
PLGA, and (C) 1 ug rhTGF-β1. 
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Figure 10. No significant differences in (A) mean diameter (p=0.99) or (B) diameter 
frequency distribution (p=0.99) of lyophilized avidin-coated PLGA microparticles. 
 
Loading of TEVG scaffolds with release vehicle 
 
 
Figure 11. Scanning electron micrograph of tubular PGA-PCLA TEVG scaffold (A) 
internal and (B) external surfaces after washing demonstrating decoration of TEVG 
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Figure 12. Total loading of TEVG scaffold with null vehicle avidin-coated PLGA 
microparticles increases with concentration of microparticles in loading solution and 
scaffold incubaton time in loading solution. 
 
 
Figure 13. Poly-L-lysine-biotin linker peptide enhances loading density of internal and 
external TEVG scaffold surfaces with null vehicle avidin-coated PLGA microparticles in 








10 30 60 10 30 60













































Figure 14. Near-UV spectral photoabsorptivity profile of SB-431542 in PBS 




Figure 15. Spectrophotometry standard curves at 320 nm for determining SB-431542 




Figure 16. (A) Absolute and (B) fractional release of SB-431542 from eluting scaffolds 
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Figure 17. Western blot demonstrating bioactivity of SB-431542 released from scaffolds 
and microparticles by reduced phosphorylation of Smad3 normalized to Smad2/3. Stock 





















































Figure 18. (A) Cell titer blue and (B) ELISA assays demonstrate that SB-431542 eluted 
from microparticles or scaffolds reduces cell viability and influences expression of 







































SB-431542 or rhTGF-β1 delivery improves TEVG patency in mouse model 
 
 
Table 1. Morphometry of TEVGs explanted at 2 weeks 
TEVG scaffold N Lumen diameter (mm) Patency 
Patent grafts  All grafts 
PGA-PCLA [historical control
22
] 25 0.72 ± 0.09 0.37 ± 0.28 36% 
PGA-PCLA(SB-431542) 25 0.72 ± 0.06 0.52 ± 0.32 70% 
PGA-PCLA + systemic SB-431542
38
 16 0.73 ± 0.06 0.67 ± 0.16 88% 
PGA-PCLA-biotin/avidin-PLGA [control] 10 0.70 ± 0.07 0.34 ± 0.31 30% 
PGA-PCLA-biotin/avidin-PLGA(SB-431542) 10 0.73 ± 0.08 0.73 ± 0.08 100% 






























p = 0.203 p = 1.000 
p = 0.003** p = 0.427 












Figure 19. Local delivery of SB-431542 by microparticle or scaffold encapsulation as 
well as local delivery of rhTGF-β1 by microparticle encapsulation prevent critical 
stenosis of a tissue engineered vascular graft during the first two weeks after implantation 
as infrarenal inferior vena cava interposition graft compared with nontherapeutic 
controls. (A) Luminal diameters are significantly greater with microparticle delivery of 
SB-431542 or rhTGF-β1 compared to nontherapeuetic controls or scaffolds 
encapsulation. (B) TEVG occlusion is significantly less common in the first two weeks 
with local delivery of SB-431542 or rhTGF-β1 by any vehicle, and is not observed with 





























p = 0.009** p = 1.000 
p = 0.003** 
p = 0.003** 
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Figure 20. Local delivery of SB-431542 or rhTGF-β1 prevents both mild and critical 
stenosis of a small diameter TEVG IVC graft by hyperplastic smooth muscle 
proliferation during the critical first two weeks in vivo. Explanted graft sections 
demonstrated complete concentric layers of endothelium (CD31, red), smooth muscle 
(SMA, green), and macrophages (F4/80, figure 21). (A) Patent SB-431542 microparticle 
TEVG, (B) patent SB-431542 dioxane TEVG, (C) critically stenosis SB-431542 dioxane 





Figure 21. Representative cross sections of explanted occluded SB-431542 eluting TEVG 
and patent microparticle TEVG demonstrate paucity of macrophage infiltration (F4/80) 
and high density of collagen (Gomori trichrome) and smooth muscle (calponin) in the 
hyperplastic luminal obstruction by immunochemical histology. Smooth muscle 
infiltration and collagen deposition was the sole observed histologic mechanism of 
TEVG failure. Neither thrombotic nor or embolic occlusion were observed. 
 
  























































Table 2. Comparison of SB-431542 delivery modalities 









Dosing once once 10 mg/kg BID IP 
Total 
administrations 




100 ug 250 ug 5.6 mg 
Encapsulation 
efficiency 




13.6 ng 1.26 ng 5.6 mg 
Cost of SB-431542 
per treatment 










The results above chronicle the development and validation of a platform for local 
delivery of therapeutics from a small diameter tissue engineered vascular graft. This 
thesis is a proof-of-concept that targeted delivery of therapeutics – one small molecule 
receptor tyrosine kinase inhibitor and one recombinant protein – can be built into a 
vascular graft and slowly released to control the development and performance of that 
graft for weeks after surgical implantation. We have also successfully demonstrated that 
this approach is a viable strategy to enhance the clinical utility of our biologic medical 
device. 
Moreover, the above data document the application of this platform for scientific 
discovery. I lead the development of this drug delivery system (specific aim 1) to aid 
Yale School of Medicine alumnus Daniel R. Duncan and our colleagues in the Breuer 
and Simons labs in validating Dr. Duncan’s investigations of the endothelial-
mesenchymal transition we observed to underlie stenosis/occlusion of IVC interposition 
TEVGs in our small and large animal models. Local delivery of SB-431542 from TEVG 
scaffolds and from microparticles tethered to TEVG scaffolds provided strong supporting 
evidence that the hyperplastic smooth muscle infiltration of the graft lumens was a TGF-
β-mediated process, one that could be intervened upon without the using of seeded cells, 
and that was not critical for TEVG formation. Application of this system has advanced 
our understanding of TEVG development in vivo and suggested a more complex role for 
TGF-β signaling in TEVG formation and behavior in vivo than previously thought. 
We can reject the null hypothesis that local delivery of SB-431542 is noninferior 
to systemic administration of SB-431542 in the prevention of EndMT-mediated 
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neointimal hyperplastic stenosis of a TEVG during the critical period for graft failure in a 
mouse model. However, a demonstration of superior efficacy (specific aim 2a) was not 
achieved: local delivery of SB-431542 was not significantly more effective than systemic 
delivery of SB-431542 in the prevention of TEVG neointimal hyperplastic stenosis. 
There was no significant difference in luminal diameters (0.67 ± 0.16 vs 0.73 ± 0.06 mm, 
p = 0.871) or patency rates (87.5% vs 100%, p = 0.508) between systemic intraperitoneal 
injections of SB-431542 in DMSO vs. microparticle delivery of SB-431542; similar 
nonsignificant differences were obtained comparing systemic to local elution of SB-
431542 from scaffolds. All methods of delivering SB-431542 prevented EndMT and 
neointimal hyperplastic critical stenosis of the TEVG to some degree (specific aim 3a). 
Failure occurred exclusively by stenosis with luminal proliferation of SMA+ cells. 
Disruption of p-Smad signaling by local delivery of SB-431542 prevented this mode of 
failure, consistent with inhibition of endothelial-mesenchymal transition and smooth 
muscle proliferation. These experiments were powered to demonstrate feasibility and 
noninferiority of local versus systemic delivery; the findings obtained support those 
hypotheses.  
A rudimentary cost analysis and review of the methods weakly suggest that local 
delivery of SB-431542 is more economical than systemic delivery of SB-431542 
(specific aim 2B). Local delivery of SB-431542 by drug-eluting scaffolds or scaffold-
bound microparticle is roughly an order of magnitude cheaper in material costs and 
requires considerably less labor, time, and continuing care than serial injections. 
Microparticle encapsulation is the least efficient (0.51% encapsulation efficiency) in 
terms of material consumption but also the most effective means of maximizing TEVG 
48 
 
patency in the critical period. Therapeutic administration from the scaffold by either 
route, which requires no additional preimplantation processing on the day of surgery or 
additional operative steps and also has less onerous postsurgical care requirements, is 
inarguable more practical for both care providers and the recipient. 
 Release studies demonstrated that the eluted SB-431542 was approximately 1/300 
the cumulative systemic dose of SB-431542 delivered intraperitoneally, and that 55% of 
this dose was delivered during the first day. SB-431542 encapsulated in the TEVG 
scaffolds is likely eluted in two peaks: an early bolus that occurs mostly over the first day 
post-implantation followed by a gradual release until a second bolus occurs when bulk 
hydrolysis completes the PGA-PCLA scaffold. Conversely, microparticles tethered to the 
scaffold delivered a cumulative SB-431542 dose one order of magnitude lower nearly 
linearly over the first week. The sustained release was significantly more efficacious in 
achieving the primary outcome of maximum graft patency at two weeks (specific aim 
2c). The capability and utility of this system for multiplexed and asymmetric drug 
delivery from multiple particle species tethered to the scaffold with or without concurrent 
release from the scaffold polymer remain to be explored. 
 The investigation of the effect and mechanism of rhTGF-β1 on TEVG formation 
and function (specific aim 3b) remains incomplete and inconclusive. The core experiment 
of local rhTGF-β1delivery in the same mouse model was completed and generated the 
very unexpected and interesting result of also achieving 100% TEVG patency. 
Unfortunately, the clinical obligations of medical school and the departure of the Breuer 
lab from Yale University prevented me from completing the necessary experiments to 
validate those findings. Bioactivity and the release profile of aqueous rhTGF-β1 eluted 
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from microparticles were never assessed: no data exist to demonstrate that rhTGF-β1 was 
actually eluted from the encapsulating particles, that any eluted rhTGF-β1 retained 
physiologic activity, or that rhTGF-β1 was delivered to the target site. Therefore, the 
unexpected and extremely desirable results obtained with rhTGF-β1-eluting scaffolds 
should not be accepted. 
Nonetheless, the only variable altered in that experiment was the inclusion of 
rhTGF-β1 in microparticles otherwise identical to those present on the control grafts, 
decorated on identical scaffolds, constructed by the same operator from the same 
materials, implanted in the same mouse linage by the same surgeon and same technique. 
It would seem very possible that rhTGF-β1 was solely responsible for the effect of 
significantly lower rate of occlusion (p = 0.003).  
This is an unexpected finding, or possible finding as above. I elected to explore 
rhTGF-β1 roughly as a control, presuming that if inhibiting the tyrosine kinase of the  
TGF-βR1/R2 receptors with SB-431542 improved patency then perhaps supplying the 
agonist would have an opposite, clinically deleterious effect – perhaps increasing smooth 
muscle hyplerplasia, potentially through EndMT, decreasing patency rates, and degrading 
clinical utility. Morphologic and immunohistochemical analyses of the explanted rhTGF-
β1 TEVGs do not provide suggestions as to why the opposite outcome was observed; 
histologic architecture is not grossly different from patent TEVGs with or without SB-
431542 treatment and cell phenotype densities are not significantly different.  
The possibility that rhTGF-β1 may have had a therapeutic effect similar to an 
antagonist of a mediator of a TGF-β1 signaling pathway suggests that the number ofTGF-
β signaling players involved in EndMT and complexity of their relationships may be 
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greater than we appreciated. Indeed, TGF-β-mediated inhibition of smooth muscle 
proliferation independent of ALK5/TGFβR1 signaling or ALK signaling altogether. 
Exploration of these prospects was to be the focus of the “fifth year” research year I 
ultimately did embark upon. 
 
Future directions 
The next step would be to investigate the role of myriad pathways of TGFb 
signaling in EnMT and neovessel formation. Perhaps selective kinase inhibition of 
ALK1/2/3/6 → p-Smad1/5 by dorsomorphin
59,60
,  ALK4/5/7 → p-Smad2/3  by SB-
431542
48
, or both Smad signaling pathways plus ALK1/ALK5 codimer activity by 
dorsomorphin and SB-431542 combined administration during TEVG formation would 
elucidate the relevance of Smad- and non-Smad dependent TGF-β signaling pathways to 
EndMT and long-term TEVG performance. Small molecule inhibitors would be 
preferable to protein agonists/antagonists for signaling manipulation in this system as 
smaller size, resilience to degradation, and lower cost would facilitate screening studies 
and future local delivery from the TEVG scaffold. 
Intervention on the most relevant TGF-β pathway(s) might become the foundation 
for future strategies to regulate TEVG growth and long-term patency. Endothelial 
specific reporter mice generated by crossing Tie2-Cre with R26R-LacZ mice would 
allow colocalization of LacZ+ with mesenchymal markers and quantification of EndMT 
in harvested TEVG.  The effect of systemic administration of each kinase inhibitor or 
combination on long term patency, stability, and growth could be assessed by quantifying 
EndMT and diameter of the neovessel lumen and wall layers at various time points.  
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Local delivery of dorsomorphin and/or SB-431542 from hydrolysable polymer 
microparticles tethered to the TEVG scaffold
61
 would both validate these preliminary 
studies and provide a cell-free TEVG scaffold amenable to use as an off-the-shelf 
vascular graft
34
. Scaling up this drug-releasing graft in a lamb model of an extracardiac 
Fontan shunt comparable in size to that used in a human child would demonstrate that 
TGF-β1 signaling inhibition improves the function of a TEVG suitable for palliation of 
hypoplastic left heart syndrome. This would open the door to application for an FDA-
sanctioned human clinical trial of a cell-free, off-the-shelf, stable, growing TEVG for 
patients with hypoplastic left heart syndrome – a major advance over the standard of care. 
Given the centrality of TGF-β signaling in embryonic cardiac development, 
further understanding of TGF-beta signaling in the tissue engineered vascular graft may 
inform tissue engineering of other cardiovascular structures. Notably, the combined 
administration SB-431542 and for dorsomorphin as porposed in herein induces the 
differentiation of endothelial cells into cardiomyocytes
59
. Delivery of these kinase 
inhibitors from a degradable scaffold may provide the foundation for myocardial patch 
design. More globally, I envision drug releasing scaffolds as tissue blueprints that will 
underpin the future of the field of tissue engineering. This proposal to explore the 
complexity of TGF-β signaling in a TEVG through local and systemic delivery of 
agonists and antagonists will become a model for “cell-free,” in-situ tissue engineering 
that combines targeted architectural intervention by surgical scaffold implantation with 
subsequent tissue building through local-drug-induced cell recruitment and pathway 
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